Capricor Therapeutics (CAPR) FCF Margin (2011 - 2024)
Capricor Therapeutics (CAPR) posted quarterly FCF Margin of 137.33% for Q4 2024, down 3679.0% year-over-year from 3.84% in Q1 2024, and up 73.34% quarter-over-quarter from 515.18% in Q3 2024.
Powered by 
Analysis
Capricor Therapeutics (CAPR) FCF Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' FCF Margin history runs 13 years deep, the most recent figure standing at 137.33% for Q4 2024.
- In Q4 2024, FCF Margin fell 3679.0% year-over-year to 137.33%; the TTM figure through Sep 2025 stood at 563.94% (down 42966.0% YoY), while the FY2024 annual figure was 184.83%, down 7796.0% from the prior year.
- FCF Margin for Q4 2024 stood at 137.33%, up from 515.18% in the prior quarter.
- The five-year high for FCF Margin was 129.32% in Q1 2023, with the low at 18558.95% in Q3 2020.
- The 5-year median for FCF Margin is 453.73% (2024), against an average of 2735.15%.
- The sharpest annual moves came in 2020 and 2021: FCF Margin tumbled 1739659 bps in 2020, then surged 188979 bps in 2021.
- Capricor Therapeutics' FCF Margin stood at 7142.52% in 2020, then surged by 67 bps to 2370.08% in 2021, then jumped by 67 bps to 791.34% in 2022, then soared by 87 bps to 100.53% in 2023, then tumbled by 37 bps to 137.33% in 2024.
- Business Quant data shows CAPR's FCF Margin at 137.33% in Q4 2024, 515.18% in Q3 2024, and 310.94% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -136.96% |
| Sep 30, 2024 | -515.18% |
| Jun 30, 2024 | -310.94% |
| Mar 31, 2024 | -18.77% |
| Dec 31, 2023 | -100.53% |
| Sep 30, 2023 | -146.53% |
| Jun 30, 2023 | -243.87% |
| Mar 31, 2023 | 129.32% |
| Dec 31, 2022 | -791.34% |
| Sep 30, 2022 | -392.27% |
| Jun 30, 2021 | -2,370.08% |
| Mar 31, 2021 | -8,247.46% |
| Dec 31, 2020 | -7,142.52% |
| Sep 30, 2020 | -18,558.95% |
| Jun 30, 2020 | -4,259.87% |
| Mar 31, 2020 | -656.01% |
| Dec 31, 2019 | -803.71% |
| Sep 30, 2019 | -1,162.36% |
| Jun 30, 2019 | -433.14% |
| Mar 31, 2019 | -697.47% |